'On consolidated basis

Quarter ended March 2025 compared with Quarter ended March 2024.

Net sales (including other operating income) of Dr Reddys Laboratories has increased 19.89% to Rs 8528.4 crore.  Sales of Pharmaceutical Services segment has gone up 1.29% to Rs 1,167.50 crore (accounting for 13.39% of total sales).  Sales of Global Generics segment has gone up 23.16% to Rs 7,536.50 crore (accounting for 86.46% of total sales).  Sales of Others segment has gone down 90.70% to Rs 13.20 crore (accounting for 0.15% of total sales).  Inter-segment sales came down from Rs 330.70 crore to Rs 211.20 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 13.93% to Rs 4,726.30 crore.  PBIT of Pharmaceutical Services segment rose 7.15% to Rs 251.80 crore (accounting for 5.33% of total PBIT).  PBIT of Global Generics segment rose 17.86% to Rs 4,470.70 crore (accoun...

• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026